ABSTRACT In vitro monocyte maturation was studied in patients with squamous cell carcinoma of the lung-limited to the ipsilateral hemithorax in 30 and more extensive in 40. The patients were studied prospectively and initial monocyte maturation was correlated with survival. Monocyte maturation in patients with limited disease before treatment ranged from 3-1 to 57-6%, with a median value of 214%. The survival of those patients in whom monocyte maturation was less than the normal range (<30-4%) was significantly shorter than the survival in those with normal maturation (p<0-05). Four of the five patients whose initial maturation was less than 10% proved to be inoperable at surgery. Patients with extensive disease had monocyte maturation ranging from 2 4 to 52-9% with a median value of 13-2%, significantly lower than in. those with limited disease (p<0025). Patients with extensive disease and low monocyte maturation survived a significantly shorter time than those with normal maturation (p<0 005). The depression of monocyte development may explain the finding of negative delayed hypersensitivity skin reactions in many patients with lung carcinoma and may prove useful as an index of prognosis.
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During the past 10 years there has been increasing interest in the role of the mononuclear phagocyte system of cells (MPS) in the host response to cancer. Monocytes have been shown to have the ability to kill tumour cells in vitro,' and the presence of macrophages within tumours has been correlated with a good prognosis. 2 Treatmnent of animals with materials that "activate" the MPS also increases their resistance to tumour challenge. 3 There have been a number of reports that monocytes from patients with cancer may function abnormally in vitro and that the degree of this abnormality may be related to prognosis. In this study we have investigated the in vitro maturation of monocytes into macrophages using cells isolated from the peripheral blood of patients with squamous cell carcinoma of the lung and related the results to patient survival.
Methods
A total of 70 patients with squamous cell carcinoma of the lung were studied during the period Twenty-four patients with limited squamous cell carcinoma of the lung came to surgery and five of these proved to be inoperable. Preoperative monocyte maturation in these five ranged from 3l1 to 24'3% with a median value of 6-1%. Median survival in this group was four months. In those who proved to be operable the range was 5*0 to 57-6% with a median of 31-3%, significantly higher than in those who were inoperable (p<0-01). Evidence of metastases 5 12 Treated with radiotherapy The second possibility is that patients with poor monocyte function are those who develop more malignant disease. If this were the case, and abnormal monocyte function preceded the development of neoplasia, then control groups matched for the presence of coexistent disease, infection, smoking and so on would be expected to contain a proportion of patients with similarly poor monocyte function. This has not been found to be the case in our studies, as yet unpublished.
The third possibility is that monocyte function is altered in patients with cancer as a result of the presence of the tumour. The evidence favours this possibility since patients with more extensive disease have significantly more depressed in vitro monocyte maturation, a finding confirmed in studies of patients with malignant melanoma4 and breast carcinoma." The implantation of tumour into animals causes depression of monocyte chemotaxis and the presence of extracts of tumour depresses a number of monocyte and macrophage functions in vitro as reviewed by James.'5 If this is the case, in vitro monocyte maturation may be reflecting production by the tumours of inhibitory materials that affect monocyte function, and possibly other anti-tumour effector mechanisms, thus explaining the relation to survival.
Poor delayed hypersensitivity skin responses to specific antigen have been correlated with poor survival in patients with lung cancer by a number of workers,'6'18 and this has been assumed to reflect depression of specific cell-mediated immune mechanisms involving the lymphocyte. However, it is now appreciated that normal mononuclear phagocytes as well as sensitised lymphocytes are necessary for the development of a positive skin response,'9 and it is therefore possible that abnormal MPS function underlies negative skin responses.20 21 
